山东医药2025，Vol.65Issue(5)：138-142,5.DOI:10.3969/j.issn.1002-266X.2025.05.029
非小细胞肺癌第三代表皮生长因子受体-酪氨酸激酶抑制剂耐药的防治策略研究进展
Research progress on prevention and treatment strategies for resistance to third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in NSCLC
彭李娜 1韩丽萍 1周金花 1边翠霞1
作者信息
- 1. 济宁市第一人民医院呼吸与危重症医学科,山东 济宁 272000
- 折叠
摘要
Abstract
Third-generation epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs)are the stan-dard first-line treatment for advanced EGFR-positive non-small-cell lung cancer(NSCLC)and they are now commonly used in clinical practice.However,resistance to these third-generation EGFR-TKIs frequently develops during treatment.To combat this resistance,combining third-generation EGFR-TKIs with chemotherapy,vascular endothelial growth factor inhibitors,and other EGFR-targeted therapies has shown promise.For NSCLC patients who develop resistance,treatment options depend on whether the mechanism of resistance is known.If the resistance mechanism is clear,patients can be treated with targeted therapies such as fourth-generation EGFR-TKI variant inhibitors,combinations of EGFR-TKIs with mesenchymal-epithelial transition(MET)inhibitors,or combinations with cyclin-dependent kinase 4/6(CDK4/6)inhibi-tors.Conversely,patients with an unclear resistance mechanism may benefit from immunotherapy and antibody-drug conju-gates.By understanding the strategies for preventing and treating resistance to third-generation EGFR-TKIs in NSCLC,we can enhance the clinical application of these therapies in the future.关键词
非小细胞肺癌/表皮生长因子受体/酪氨酸激酶抑制剂/靶向治疗/耐药Key words
non-small-cell lung cancer/epidermal growth factor receptor/tyrosine kinase inhibitor/targeted thera-py/drug resistance分类
临床医学引用本文复制引用
彭李娜,韩丽萍,周金花,边翠霞..非小细胞肺癌第三代表皮生长因子受体-酪氨酸激酶抑制剂耐药的防治策略研究进展[J].山东医药,2025,65(5):138-142,5.
